Search | Clinical Trials Finder

Conditions: Anthocyanin Metabolism
Interventions: omeprazole, placebo; Drug
Lead sponsor: USDA Beltsville Human Nutrition Research Center; Federal
Eligibility: 22 Years to 59 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Chronic Rhinosinusitis Without Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more

Conditions: Healthy
Interventions: Palbociclib Alone, Palbociclib + Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 3
States / cities: Miami, Florida • South Miami, Florida

Conditions: Type1diabetes
Interventions: SteadiSet Extended Wear Infusion Set; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 15
States / cities: Newport Beach, California • Stanford, California • Aurora, Colorado + 12 more

Conditions: Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
Interventions: FOLFOX, 5-FU, Erlotinib; Drug
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Primary Immunodeficiency
Interventions: Gamunex-C, IVIG-PEG; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more

Conditions: Type 1 Diabetes, Gastroparesis Due to Diabetes Mellitus Type I
Interventions: Medtronic 780G AID; Device
Lead sponsor: Viral N. Shah; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Social Psychology
Interventions: Intranasal oxytocin, Intranasal placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 30 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Barrett Esophagus, Gastroesophageal Reflux
Interventions: Zegerid (proton pump inhibitor), Bravo pH monitoring; Drug · Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Bihormonal iLet Bionic Pancreas, Insulin-only Bionic Pancreas, Dasiglucagon; Device · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Pumping
Interventions: Text message including biomarker of breast pumping adequacy; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease
Interventions: ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD; Combination Product · Drug
Lead sponsor: NeuroDerm Ltd.; Industry
Eligibility: 30 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions: intravascular ventricular assist system (iVAS); Device
Lead sponsor: NuPulseCV; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 18
States / cities: Washington D.C., District of Columbia • Orlando, Florida • Chicago, Illinois + 14 more

Conditions: Barrett Esophagus
Interventions: Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 19
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 15 more

Conditions: Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions: gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM), Automated Insulin Delivery (AID) System; Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Gastroesophageal Reflux Disease
Interventions: arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 62
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more

Conditions: Type 1 Diabetes
Interventions: Predictive Hyperglycemia Minimization Algorithm, Predictive Hypoglycemia Minimization Algorithm; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 15 Years to 45 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Postoperative Pain
Interventions: Patient-Controlled Analgesia pump with Cues, Patient-Controlled Analgesia pump without Cues, Morphine; Device · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 7 Years to 18 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Ischemia-Reperfusion Injury, Kidney Diseases
Interventions: Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Philadelphia, Pennsylvania

Conditions: Squamous Cell Carcinoma of Skin, Carcinoma, Squamous Cell
Interventions: Pegylated Interferon alpha-2b, Capecitabine, 5-FU; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Type 1 Diabetes Mellitus
Interventions: The MiniMed Paradigm® X54 System; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 16 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Escondido, California • Stanford, California • Aurora, Colorado + 2 more

Conditions: Hysterectomy, Gynecologic Surgical Procedures, Narcotic Use, Pain, Postoperative
Interventions: Ropivacaine Infusion from ON-Q Pump, Ropivacaine + Ketorolac Infusion from ON-Q Pump, Normal Saline Infusion from ON-Q Pump; Drug
Lead sponsor: Ying Liu; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Overweight, Obesity
Interventions: Weight loss; Behavioral
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Greensboro, North Carolina

Search by objective public record fields.

Gastric pH and Anthocyanin Absorption

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes

Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

Oxytocin and Learning for Teaching

Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus

The Bihormonal iLet Bionic Pancreas Feasibility Study

Improving Lactation Success in Mothers of Critically Infants

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

Feasibility Study of the Intravascular Ventricular Assist System (iVAS)

Ablation of Intestinal Metaplasia Containing Dysplasia

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms

Patient Controlled Analgesia Pump Cues on Patient Satisfaction

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System

Intraperitoneal Infusion of Analgesic for Postoperative Pain Management

Get Active and Eat Right: Moms at Work